Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB101 in advanced solid tumors
NCT05821777Phase 2Terminated
- Sponsor
- Centessa Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of LB101 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Cervical Cancer (CC) and 4 more, sponsored by Centessa Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events at 3 years and 2 more. Started Mar 2023; status: terminated.
02
Drugs
LB101
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Cervical Cancer (CC)cutaneous squamous cell carcinoma (cSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05821777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821777.